In Vitro ADME & Drug-Drug Interaction Considerations for Toxicologists
Presenter: Pallavi Limaye, Ph.D., DABT, XenoTech Director of Scientific Consulting with special Q&A guest, Brian Ogilvie, Ph.D., XenoTech Vice President of Scientific Consulting
Originally scheduled to be presented at the canceled Society of Toxicology (SOT) 59th Annual Meeting & ToxExpo, our experts are bringing the tradeshow to you! Dr. Limaye will be discussing the intersection of ADME and toxicology in this webinar, followed by a live Q&A to address audience questions and comments.
In vitro ADME and drug-drug interaction (DDI) investigations are early activities in the drug development process that are critical for framing downstream decision making. This ADME 101 webinar will provide insights at a high-level related to regulatory drivers, investigatory objectives, and practical concerns for such studies that are relevant to interested general toxicologists. Participants will gain insight as to the critical need and utility for in vitro ADME and DDI investigations as related to drug development. Regulatory expectations will be reviewed as will points of particular interest for enabling successful achievement of investigatory goals.
- Why run these studies?
- Predominant types of in vitro ADME & Drug-Drug Interaction (DDI) studies
- When to conduct these studies
- Areas of concern: Proper design & interpretation
- And other highlights and information…
What topic would you like to hear about?
Our experts are constantly on the hunt for new and exciting topics to present on, and nothing helps us figure out what you want to hear more than requests and feedback! Use our form to submit your request so we can continue producing educational materials you look forward to
